| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antihypertensive Agents | 27 | 2021 | 1962 | 4.81 | Why? |
| Hypertension | 37 | 2021 | 8895 | 4.18 | Why? |
| Blood Pressure | 20 | 2019 | 2198 | 3.65 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 6 | 2020 | 520 | 3.05 | Why? |
| Tetrazoles | 5 | 2018 | 262 | 2.70 | Why? |
| Olmesartan Medoxomil | 3 | 2021 | 9 | 2.32 | Why? |
| Cardiovascular Diseases | 20 | 2021 | 11497 | 1.96 | Why? |
| Renin-Angiotensin System | 13 | 2021 | 3661 | 1.71 | Why? |
| Uncoupling Protein 2 | 3 | 2017 | 10 | 1.61 | Why? |
| Arterial Pressure | 3 | 2021 | 208 | 1.46 | Why? |
| Imidazoles | 3 | 2018 | 631 | 1.40 | Why? |
| Atrial Natriuretic Factor | 5 | 2018 | 75 | 1.29 | Why? |
| Blood Pressure Monitoring, Ambulatory | 3 | 2018 | 341 | 1.24 | Why? |
| Angiotensin Receptor Antagonists | 9 | 2021 | 3892 | 1.22 | Why? |
| Hypercholesterolemia | 2 | 2018 | 175 | 1.20 | Why? |
| Hypotension | 2 | 2019 | 392 | 1.18 | Why? |
| Blood Pressure Determination | 5 | 2019 | 450 | 1.14 | Why? |
| Natriuretic Peptides | 2 | 2020 | 66 | 0.94 | Why? |
| Risk Reduction Behavior | 2 | 2020 | 946 | 0.92 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 9 | 2021 | 5277 | 0.92 | Why? |
| Atherosclerosis | 2 | 2019 | 768 | 0.85 | Why? |
| Smoke-Free Policy | 1 | 2021 | 52 | 0.85 | Why? |
| Heart Failure | 12 | 2021 | 6638 | 0.83 | Why? |
| Cardiology | 3 | 2020 | 2873 | 0.77 | Why? |
| Valsartan | 2 | 2018 | 206 | 0.77 | Why? |
| Hypolipidemic Agents | 3 | 2018 | 208 | 0.76 | Why? |
| Peer Influence | 1 | 2018 | 24 | 0.74 | Why? |
| Masked Hypertension | 1 | 2018 | 15 | 0.74 | Why? |
| White Coat Hypertension | 1 | 2018 | 24 | 0.73 | Why? |
| Angina, Unstable | 1 | 2018 | 110 | 0.70 | Why? |
| Stroke | 8 | 2018 | 8839 | 0.70 | Why? |
| Ambulatory Care | 4 | 2020 | 4947 | 0.69 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2018 | 1510 | 0.68 | Why? |
| Hematinics | 1 | 2017 | 48 | 0.68 | Why? |
| Aminobutyrates | 1 | 2018 | 142 | 0.66 | Why? |
| Primary Prevention | 3 | 2018 | 778 | 0.64 | Why? |
| Rats, Inbred SHR | 5 | 2018 | 58 | 0.64 | Why? |
| Cardiomyopathy, Hypertrophic | 5 | 2018 | 193 | 0.63 | Why? |
| Vasodilation | 4 | 2019 | 258 | 0.60 | Why? |
| Outpatient Clinics, Hospital | 1 | 2020 | 523 | 0.58 | Why? |
| Mutation, Missense | 2 | 2018 | 863 | 0.58 | Why? |
| Life Style | 2 | 2018 | 2708 | 0.58 | Why? |
| Occupational Health Services | 1 | 2018 | 219 | 0.56 | Why? |
| Preventive Health Services | 1 | 2020 | 501 | 0.55 | Why? |
| Organ Specificity | 1 | 2019 | 1070 | 0.55 | Why? |
| Cardiorespiratory Fitness | 1 | 2018 | 313 | 0.54 | Why? |
| Cardiovascular Agents | 1 | 2020 | 663 | 0.53 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.53 | Why? |
| Healthy Lifestyle | 1 | 2018 | 447 | 0.51 | Why? |
| Myocardial Infarction | 3 | 2018 | 3361 | 0.49 | Why? |
| Risk Factors | 30 | 2021 | 71621 | 0.49 | Why? |
| Angiotensin II Type 2 Receptor Blockers | 1 | 2012 | 69 | 0.47 | Why? |
| Takotsubo Cardiomyopathy | 4 | 2019 | 453 | 0.47 | Why? |
| Appointments and Schedules | 1 | 2020 | 1204 | 0.47 | Why? |
| Lipids | 2 | 2018 | 1079 | 0.46 | Why? |
| Benzoates | 1 | 2012 | 102 | 0.46 | Why? |
| Acute Lung Injury | 1 | 2020 | 904 | 0.45 | Why? |
| Angioedema | 1 | 2013 | 111 | 0.44 | Why? |
| Polypharmacy | 1 | 2014 | 347 | 0.44 | Why? |
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 3 | 2019 | 11 | 0.43 | Why? |
| Valine | 1 | 2012 | 359 | 0.42 | Why? |
| Precision Medicine | 2 | 2017 | 1477 | 0.41 | Why? |
| Anemia | 1 | 2017 | 789 | 0.40 | Why? |
| Endothelium, Vascular | 5 | 2019 | 1751 | 0.39 | Why? |
| Benzimidazoles | 1 | 2012 | 275 | 0.39 | Why? |
| Malaria | 1 | 2019 | 1097 | 0.38 | Why? |
| Oxidative Stress | 7 | 2019 | 2050 | 0.38 | Why? |
| Gene Expression Regulation | 3 | 2019 | 4020 | 0.37 | Why? |
| MicroRNAs | 3 | 2019 | 1787 | 0.35 | Why? |
| Neprilysin | 2 | 2019 | 112 | 0.35 | Why? |
| Humans | 88 | 2021 | 930598 | 0.34 | Why? |
| Acute Coronary Syndrome | 2 | 2018 | 2107 | 0.34 | Why? |
| Ventricular Dysfunction, Left | 3 | 2019 | 993 | 0.33 | Why? |
| Societies, Medical | 3 | 2020 | 6907 | 0.33 | Why? |
| Rats | 6 | 2019 | 2764 | 0.32 | Why? |
| Kidney | 2 | 2017 | 3648 | 0.31 | Why? |
| Radial Artery | 1 | 2006 | 132 | 0.30 | Why? |
| Workplace | 1 | 2018 | 2075 | 0.30 | Why? |
| Treatment Outcome | 15 | 2021 | 51732 | 0.28 | Why? |
| Health Promotion | 1 | 2018 | 2020 | 0.28 | Why? |
| Calcium Channel Blockers | 2 | 2017 | 367 | 0.27 | Why? |
| Diastole | 2 | 2018 | 168 | 0.27 | Why? |
| Medication Adherence | 3 | 2019 | 1270 | 0.25 | Why? |
| Epigenesis, Genetic | 3 | 2018 | 711 | 0.25 | Why? |
| Brain | 2 | 2017 | 5133 | 0.25 | Why? |
| Time Factors | 9 | 2020 | 31397 | 0.24 | Why? |
| Exercise Test | 1 | 2009 | 911 | 0.24 | Why? |
| Heart Rate | 4 | 2019 | 1527 | 0.24 | Why? |
| Italy | 17 | 2021 | 38444 | 0.23 | Why? |
| Stroke Volume | 3 | 2019 | 2153 | 0.23 | Why? |
| Risk Assessment | 9 | 2021 | 25439 | 0.23 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.23 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.23 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.22 | Why? |
| Drug Therapy, Combination | 4 | 2018 | 7268 | 0.21 | Why? |
| Aspirin | 2 | 2019 | 1043 | 0.21 | Why? |
| Nuclear Receptor Coactivator 1 | 1 | 2019 | 2 | 0.20 | Why? |
| Ventricular Function, Left | 2 | 2019 | 1555 | 0.20 | Why? |
| Proto-Oncogene Proteins c-jun | 1 | 2019 | 21 | 0.20 | Why? |
| Inflammation | 3 | 2018 | 13255 | 0.20 | Why? |
| Cote d'Ivoire | 1 | 2019 | 115 | 0.20 | Why? |
| Economics, Nursing | 1 | 2018 | 2 | 0.20 | Why? |
| Nitric Oxide | 1 | 2006 | 769 | 0.20 | Why? |
| Jumonji Domain-Containing Histone Demethylases | 1 | 2019 | 28 | 0.20 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.19 | Why? |
| Nursing Service, Hospital | 1 | 2018 | 7 | 0.19 | Why? |
| Receptor, Angiotensin, Type 1 | 1 | 2020 | 160 | 0.19 | Why? |
| Drug Resistance | 2 | 2019 | 395 | 0.19 | Why? |
| Isoproterenol | 1 | 2018 | 31 | 0.19 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.19 | Why? |
| Patient Selection | 3 | 2018 | 4560 | 0.19 | Why? |
| Cyclic GMP | 1 | 2018 | 50 | 0.18 | Why? |
| Electron Transport Complex I | 1 | 2017 | 12 | 0.18 | Why? |
| Vascular Endothelial Growth Factors | 1 | 2018 | 29 | 0.18 | Why? |
| Clinical Governance | 1 | 2018 | 59 | 0.18 | Why? |
| Oxidation-Reduction | 2 | 2018 | 540 | 0.18 | Why? |
| Phthalazines | 1 | 2018 | 26 | 0.18 | Why? |
| Animals | 16 | 2019 | 78931 | 0.18 | Why? |
| Automobiles | 1 | 2018 | 88 | 0.18 | Why? |
| Sodium Chloride Symporter Inhibitors | 1 | 2017 | 45 | 0.18 | Why? |
| Drug Combinations | 2 | 2018 | 3852 | 0.18 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.18 | Why? |
| Diagnosis-Related Groups | 1 | 2018 | 167 | 0.17 | Why? |
| Vascular Remodeling | 1 | 2018 | 99 | 0.17 | Why? |
| Chromatin Assembly and Disassembly | 1 | 2017 | 62 | 0.17 | Why? |
| Fenofibrate | 1 | 2017 | 22 | 0.17 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.17 | Why? |
| Reactive Oxygen Species | 6 | 2019 | 1136 | 0.17 | Why? |
| Pseudoxanthoma Elasticum | 1 | 2016 | 9 | 0.17 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2019 | 10649 | 0.17 | Why? |
| Pharmacogenomic Variants | 1 | 2017 | 112 | 0.17 | Why? |
| Flavonoids | 1 | 2002 | 492 | 0.17 | Why? |
| Brassica | 1 | 2017 | 66 | 0.17 | Why? |
| Venous Insufficiency | 1 | 2017 | 22 | 0.17 | Why? |
| Cyclic AMP | 1 | 2017 | 76 | 0.17 | Why? |
| rac1 GTP-Binding Protein | 1 | 2017 | 32 | 0.17 | Why? |
| Sympathectomy | 1 | 2017 | 67 | 0.17 | Why? |
| Manufacturing Industry | 1 | 2018 | 90 | 0.17 | Why? |
| Systole | 1 | 2018 | 252 | 0.17 | Why? |
| Repressor Proteins | 1 | 2019 | 232 | 0.17 | Why? |
| Biphenyl Compounds | 1 | 2018 | 249 | 0.17 | Why? |
| NADPH Oxidase 2 | 1 | 2017 | 58 | 0.17 | Why? |
| Cardiomyopathy, Restrictive | 1 | 2016 | 30 | 0.17 | Why? |
| Sodium Chloride, Dietary | 1 | 2017 | 62 | 0.17 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.17 | Why? |
| Platelet Aggregation Inhibitors | 2 | 2018 | 1671 | 0.16 | Why? |
| Aminoquinolines | 1 | 2017 | 63 | 0.16 | Why? |
| Saphenous Vein | 1 | 2017 | 67 | 0.16 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.16 | Why? |
| Vasoconstriction | 1 | 2018 | 153 | 0.16 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2018 | 192 | 0.16 | Why? |
| Diabetic Cardiomyopathies | 1 | 2017 | 79 | 0.16 | Why? |
| Immunoglobulin Light-chain Amyloidosis | 1 | 2016 | 94 | 0.16 | Why? |
| Myocardium | 2 | 2019 | 2323 | 0.15 | Why? |
| Regenerative Medicine | 1 | 2017 | 161 | 0.15 | Why? |
| Pneumonia, Viral | 9 | 2021 | 243684 | 0.15 | Why? |
| Guideline Adherence | 2 | 2019 | 2309 | 0.15 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 286 | 0.15 | Why? |
| Male | 34 | 2021 | 367725 | 0.15 | Why? |
| Death, Sudden, Cardiac | 2 | 2018 | 522 | 0.15 | Why? |
| Protective Factors | 2 | 2018 | 1720 | 0.15 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.14 | Why? |
| Platelet Aggregation | 1 | 2017 | 318 | 0.14 | Why? |
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 231 | 0.14 | Why? |
| Electrocardiography | 6 | 2018 | 3957 | 0.14 | Why? |
| Polymorphism, Genetic | 2 | 2017 | 1074 | 0.14 | Why? |
| Ventricular Remodeling | 1 | 2018 | 349 | 0.14 | Why? |
| Up-Regulation | 2 | 2020 | 2249 | 0.14 | Why? |
| Proteinuria | 1 | 2018 | 474 | 0.14 | Why? |
| Databases, Factual | 3 | 2019 | 6248 | 0.14 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.14 | Why? |
| Disease Susceptibility | 2 | 2019 | 4002 | 0.14 | Why? |
| Angiotensin II | 1 | 2020 | 601 | 0.14 | Why? |
| Troponin | 1 | 2020 | 1058 | 0.13 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.13 | Why? |
| Ultrasonography, Doppler | 1 | 2017 | 406 | 0.13 | Why? |
| Female | 30 | 2021 | 380317 | 0.13 | Why? |
| Pacemaker, Artificial | 1 | 2018 | 431 | 0.13 | Why? |
| Coronary Artery Disease | 2 | 2018 | 2570 | 0.13 | Why? |
| Catheter Ablation | 1 | 2017 | 438 | 0.12 | Why? |
| Methyltransferases | 1 | 2019 | 720 | 0.12 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.12 | Why? |
| Aged | 20 | 2021 | 215776 | 0.12 | Why? |
| Patient Admission | 2 | 2020 | 5250 | 0.12 | Why? |
| Genetic Predisposition to Disease | 4 | 2018 | 4027 | 0.12 | Why? |
| Biomarkers | 5 | 2020 | 23361 | 0.12 | Why? |
| Evidence-Based Medicine | 2 | 2017 | 3228 | 0.12 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.11 | Why? |
| Pneumococcal Vaccines | 1 | 2017 | 571 | 0.11 | Why? |
| Cell Survival | 1 | 2017 | 1581 | 0.11 | Why? |
| Middle Aged | 25 | 2021 | 270681 | 0.11 | Why? |
| Obesity | 4 | 2020 | 7388 | 0.11 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.11 | Why? |
| Defibrillators, Implantable | 1 | 2018 | 624 | 0.11 | Why? |
| Percutaneous Coronary Intervention | 2 | 2018 | 3646 | 0.11 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.11 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.10 | Why? |
| Cardiovascular System | 1 | 2018 | 750 | 0.10 | Why? |
| Smoking | 2 | 2021 | 3358 | 0.10 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.10 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.10 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.10 | Why? |
| Delivery, Obstetric | 1 | 2019 | 1292 | 0.10 | Why? |
| Heart Ventricles | 1 | 2018 | 1139 | 0.10 | Why? |
| Hormone Antagonists | 1 | 2009 | 29 | 0.10 | Why? |
| Renal Insufficiency, Chronic | 2 | 2021 | 2654 | 0.10 | Why? |
| Cardiomyopathies | 1 | 2019 | 997 | 0.10 | Why? |
| Incidence | 4 | 2020 | 25622 | 0.10 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.09 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.09 | Why? |
| Patient Compliance | 1 | 2019 | 1468 | 0.09 | Why? |
| Vascular Diseases | 1 | 2017 | 846 | 0.09 | Why? |
| Cesarean Section | 1 | 2019 | 2089 | 0.09 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.09 | Why? |
| Hypoglycemic Agents | 2 | 2018 | 2165 | 0.09 | Why? |
| Physical Endurance | 1 | 2009 | 107 | 0.09 | Why? |
| Prognosis | 7 | 2020 | 32490 | 0.09 | Why? |
| Erythropoietin | 1 | 2009 | 167 | 0.09 | Why? |
| Hypertension, Pulmonary | 1 | 2017 | 970 | 0.09 | Why? |
| omega-N-Methylarginine | 1 | 2006 | 5 | 0.09 | Why? |
| Nitric Oxide Synthase | 1 | 2006 | 37 | 0.08 | Why? |
| Hyperglycemia | 1 | 2018 | 1363 | 0.08 | Why? |
| Adult | 16 | 2021 | 244371 | 0.08 | Why? |
| Mass Vaccination | 1 | 2017 | 1101 | 0.08 | Why? |
| Cohort Studies | 4 | 2018 | 36005 | 0.08 | Why? |
| Nitroglycerin | 1 | 2006 | 39 | 0.08 | Why? |
| Hyperemia | 1 | 2006 | 62 | 0.08 | Why? |
| Drug Interactions | 1 | 2014 | 1653 | 0.08 | Why? |
| Endothelial Cells | 1 | 2017 | 2048 | 0.08 | Why? |
| Blood Glucose | 2 | 2018 | 3642 | 0.08 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2009 | 801 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Cross-Sectional Studies | 8 | 2021 | 53120 | 0.08 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.08 | Why? |
| Phenotype | 3 | 2017 | 4037 | 0.08 | Why? |
| Self Care | 1 | 2014 | 918 | 0.07 | Why? |
| Blood Flow Velocity | 1 | 2006 | 193 | 0.07 | Why? |
| Drug Prescriptions | 1 | 2014 | 1062 | 0.07 | Why? |
| Pedigree | 1 | 2006 | 502 | 0.07 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.07 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.07 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.07 | Why? |
| Diet | 1 | 2017 | 2052 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.07 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.07 | Why? |
| Chi-Square Distribution | 2 | 2018 | 961 | 0.07 | Why? |
| Genetic Linkage | 1 | 2004 | 87 | 0.07 | Why? |
| Arrhythmias, Cardiac | 1 | 2018 | 2510 | 0.07 | Why? |
| Oxygen Consumption | 1 | 2009 | 711 | 0.07 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2017 | 6166 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.07 | Why? |
| Vasodilator Agents | 1 | 2006 | 344 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.06 | Why? |
| Emergencies | 1 | 2018 | 4095 | 0.06 | Why? |
| Research Design | 2 | 2017 | 5830 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.06 | Why? |
| Follow-Up Studies | 5 | 2019 | 17020 | 0.06 | Why? |
| Disease Models, Animal | 4 | 2019 | 10998 | 0.06 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.06 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.05 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Retrospective Studies | 8 | 2018 | 105322 | 0.05 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.05 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2017 | 3051 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Antioxidants | 2 | 2018 | 1593 | 0.05 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Prospective Studies | 4 | 2019 | 43301 | 0.05 | Why? |
| Disease Progression | 3 | 2020 | 13580 | 0.05 | Why? |
| Mice, Mutant Strains | 1 | 2019 | 42 | 0.05 | Why? |
| Hospitals, Teaching | 2 | 2018 | 1609 | 0.05 | Why? |
| Registries | 1 | 2019 | 12327 | 0.05 | Why? |
| Transcription Factor AP-1 | 1 | 2019 | 75 | 0.05 | Why? |
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2018 | 2 | 0.05 | Why? |
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 82 | 0.05 | Why? |
| PPAR gamma | 1 | 2019 | 102 | 0.05 | Why? |
| Mice | 4 | 2019 | 21357 | 0.05 | Why? |
| Simvastatin | 1 | 2018 | 63 | 0.04 | Why? |
| Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 61 | 0.04 | Why? |
| Transcriptional Activation | 1 | 2019 | 196 | 0.04 | Why? |
| Rosuvastatin Calcium | 1 | 2018 | 89 | 0.04 | Why? |
| Diet, High-Fat | 1 | 2019 | 161 | 0.04 | Why? |
| Oxidative Phosphorylation | 1 | 2017 | 120 | 0.04 | Why? |
| Maternal Age | 1 | 2019 | 244 | 0.04 | Why? |
| NADPH Oxidases | 1 | 2018 | 80 | 0.04 | Why? |
| Exercise | 1 | 2018 | 6771 | 0.04 | Why? |
| Metabolism, Inborn Errors | 1 | 2017 | 51 | 0.04 | Why? |
| Coronary Angiography | 2 | 2018 | 2275 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2019 | 5542 | 0.04 | Why? |
| Ubiquinone | 1 | 2017 | 91 | 0.04 | Why? |
| NADP | 1 | 2017 | 41 | 0.04 | Why? |
| Analysis of Variance | 1 | 2021 | 950 | 0.04 | Why? |
| Mitochondrial Diseases | 1 | 2017 | 62 | 0.04 | Why? |
| Nitric Oxide Synthase Type III | 1 | 2017 | 87 | 0.04 | Why? |
| Mitochondrial Proteins | 1 | 2017 | 152 | 0.04 | Why? |
| Immunoblotting | 1 | 2017 | 180 | 0.04 | Why? |
| Echocardiography, Doppler | 1 | 2018 | 269 | 0.04 | Why? |
| Coronary Restenosis | 1 | 2018 | 153 | 0.04 | Why? |
| Autonomic Nervous System | 1 | 2018 | 148 | 0.04 | Why? |
| Blotting, Western | 1 | 2019 | 863 | 0.04 | Why? |
| Triglycerides | 1 | 2019 | 478 | 0.04 | Why? |
| Enzyme Inhibitors | 1 | 2006 | 1881 | 0.04 | Why? |
| Anticholesteremic Agents | 1 | 2018 | 186 | 0.04 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Hospital Costs | 1 | 2018 | 274 | 0.04 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.04 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.04 | Why? |
| Multimorbidity | 1 | 2020 | 703 | 0.04 | Why? |
| Systems Biology | 1 | 2017 | 320 | 0.04 | Why? |
| Age of Onset | 1 | 2017 | 557 | 0.04 | Why? |
| International Classification of Diseases | 1 | 2017 | 265 | 0.04 | Why? |
| Protein Subunits | 1 | 2017 | 755 | 0.04 | Why? |
| Myocardial Revascularization | 1 | 2017 | 267 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2019 | 694 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Chronic Disease | 2 | 2021 | 5139 | 0.03 | Why? |
| Lipid Metabolism | 1 | 2019 | 572 | 0.03 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.03 | Why? |
| Rare Diseases | 1 | 2018 | 373 | 0.03 | Why? |
| Vasoconstrictor Agents | 1 | 2018 | 714 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 669 | 0.03 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.03 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.03 | Why? |
| Sex Factors | 2 | 2021 | 11014 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Echocardiography | 2 | 2017 | 3661 | 0.03 | Why? |
| Down-Regulation | 1 | 2019 | 1416 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2019 | 1326 | 0.03 | Why? |
| Myocytes, Cardiac | 1 | 2019 | 804 | 0.03 | Why? |
| Weight Loss | 1 | 2018 | 826 | 0.03 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
| Delivery of Health Care | 2 | 2019 | 15909 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Dyslipidemias | 1 | 2018 | 791 | 0.03 | Why? |
| RNA | 1 | 2019 | 1278 | 0.03 | Why? |
| Pneumococcal Infections | 1 | 2017 | 562 | 0.03 | Why? |
| Signal Transduction | 2 | 2018 | 7207 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Ultrasonography | 1 | 2006 | 4409 | 0.03 | Why? |
| Genotype | 2 | 2017 | 4697 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Smoking Cessation | 1 | 2018 | 826 | 0.02 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.02 | Why? |
| Frailty | 1 | 2021 | 1432 | 0.02 | Why? |
| Health Care Surveys | 1 | 2018 | 2942 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.02 | Why? |
| Cells, Cultured | 1 | 2019 | 5835 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Fatal Outcome | 1 | 2016 | 3438 | 0.02 | Why? |
| Equipment Design | 1 | 2017 | 3095 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.02 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.02 | Why? |
| Diabetes Mellitus | 2 | 2018 | 8207 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Skin | 1 | 2016 | 2096 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Atrial Fibrillation | 1 | 2017 | 2320 | 0.02 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2009 | 3776 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2016 | 6551 | 0.01 | Why? |
| Recombinant Proteins | 1 | 2009 | 3786 | 0.01 | Why? |
| Gene Frequency | 1 | 2003 | 1210 | 0.01 | Why? |
| Double-Blind Method | 1 | 2009 | 5988 | 0.01 | Why? |
| Infant, Newborn | 1 | 2019 | 23105 | 0.01 | Why? |
| Databases, Genetic | 1 | 2003 | 1127 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |